Related Experiment Video
Updated: May 22, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Red carpeting the newer antidiabetics
1Registrar, AMC, 3 Floor, Medwin Hospital, Chirag Ali lane, Nampally, Hyderabad, Andhra Pradesh, India.
Journal of Pharmacology & Pharmacotherapeutics
|May 26, 2012
Summary
Newer antidiabetic medications offer improved diabetes management. This review covers novel agents like SGLT2 inhibitors and GLP-1 analogues, enhancing treatment options for global diabetes care.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Global diabetes prevalence is rising, necessitating advanced therapeutic strategies.
- Enhanced understanding of diabetes pathophysiology drives the development of novel antidiabetic agents.
- Existing treatments require supplementation with innovative options to combat the disease effectively.
Purpose of the Study:
- To review emerging antidiabetic drugs and their mechanisms of action.
- To present an overview of newer therapeutic agents for diabetes management.
- To highlight advancements in pharmacological interventions for diabetes.
Main Methods:
- Literature review of recent antidiabetic drug development.
- Analysis of pharmacological data for novel agents.
- Synthesis of information on therapeutic targets in diabetes.
Main Results:
- Identified several classes of new antidiabetic drugs including Sodium-Glucose Transport Proteins-2 (SGLT2) inhibitors, dipeptidyl peptidase IV (DPP-IV) inhibitors, glucagon-like peptide (GLP) analogues, glucokinase activators, dual peroxisome proliferator-activated receptor (PPAR) agonists, monoclonal antibodies, and dopamine-2 receptor agonists.
- These agents offer diverse mechanisms for glycemic control.
- They can be used as monotherapy or in combination with existing oral hypoglycemic agents.
Conclusions:
- Novel antidiabetic agents represent a significant advancement in diabetes treatment.
- These drugs target various pathways, offering personalized therapeutic approaches.
- The continued development of innovative treatments is crucial for managing the global diabetes epidemic.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...